Core Insights - Medtronic plc (MDT) presented the two-year results of the SMART trial, the largest international head-to-head trial comparing TAVR options for patients with aortic stenosis and small aortic annulus at the CRT 2025 conference [1][2][6] Company Performance - The SMART trial results indicate that the Evolut TAVR valve outperforms the SAPIEN TAVR valve, showing significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less hemodynamic structural valve dysfunction [5][6] - Following the news, MDT's share price increased by 0.01% to $94.51, reflecting positive market sentiment towards the company's Structural Heart business [3] - Medtronic has a market capitalization of $121.20 billion and has delivered an average earnings surprise of 1.75% over the last four quarters [4] Industry Outlook - The global transcatheter aortic valve replacement market is projected to grow at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2030, driven by the rising prevalence of aortic stenosis, increasing preference for minimally invasive procedures, and a growing geriatric population [7]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 22, 2024. (State or other jurisdiction of incorporation or organization) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANTERIS TECHNOLOGIES GLOBAL CORP. (Exact name of registrant as specified in its charter) Delaware Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 3842 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification N ...